Tradestie Institutional Equity Comparison Engine

NVS vs GILD โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

GILD Overall Edge

GILD Captures Institutional Edge (4โ€“0 Pillars ยท 4โ€“6 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Gilead Sciences Inc (GILD) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, NVS trades at 16.2x Forward P/E with 34.0% operating margin (+4.7% YoY revenue) versus GILD at 16.6x Forward P/E and 38.2% operating margin (+6.8% YoY). In options structure, NVS sits in UNCLASSIFIED (6th %ile IV; Dealer Gamma Walls on Pro) against GILD sits in SURGE (10th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner GILD
NVS 16.2x vs GILD 16.6x Fwd P/E
Growth & Margin Winner GILD
Op Margin 34.0% vs 38.2% ยท YoY +4.7% vs +6.8%
Momentum & Technical Winner GILD
1Y +22.5% vs +35.1% ยท 52W Pos 81% vs 88%
Options & Structure Winner GILD
UNCLASSIFIED (6th %ile IV) vs SURGE (10th %ile IV)
NVS NYSE
Novartis AG
Pharmaceutical Preparations
$161.59
+0.68% 1D
Market Cap $302.9B
1M Return +7.28%
1Y Return +22.5%
Forward P/E 16.2x
Unified AI Score
41.5 / 100 SELL
Tech 29.0 Fund 38.0 Flow 50.0 Mom 21.1
GILD NASDAQ
Gilead Sciences Inc
Biological Products, (No Disgnostic Substances)
$169.09
+0.6% 1D
Market Cap $208.3B
1M Return +8.26%
1Y Return +35.06%
Forward P/E 16.6x
Unified AI Score
40.1 / 100 SELL
Tech 24.0 Fund 47.0 Flow 70.0 Mom 46.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: NVS +22.5% GILD +35.06% Spread: +12.56 pp (GILD Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
NVS TTM Op. Margin: 34.0% GILD TTM Op. Margin: 38.2%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NVS vs GILD. Trailing 12-month operating profitability (NVS 34.0% vs GILD 38.2%) and valuation multiples (NVS 16.2x vs GILD 16.6x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: NVS (6) vs GILD (4)
Institutional Metric NVS GILD Criterion Row Winner
Market Capitalization Scale $302.9B $208.3B Larger Scale NVS
Trailing P/E Ratio Valuation 30.6x 17.0x Lower Multiple GILD
Forward P/E Ratio Valuation 16.2x 16.6x Lower Multiple NVS
Revenue Growth (YoY) Growth +4.7% +6.8% Higher Growth GILD
Operating Margin (TTM) Profitability 34.0% 38.2% Higher Margin GILD
Net Profit Margin Profitability 17.5% -12.5% Higher Margin NVS
Return on Equity (ROE) Capital Efficiency 24.3% -22.4% Higher ROE NVS
52-Week Range Position Momentum 81% ($123โ€“$170) 88% ($117โ€“$177) Stronger Trend GILD
Beta / 30D Volatility Risk Regime 0.31ฮฒ ยท 27% Vol 0.34ฮฒ ยท 32% Vol Lower Realized Risk NVS
Unified Institutional Score Composite Signal 41.5 / 100 (SELL) 40.1 / 100 (SELL) Higher Composite NVS

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full NVS vs GILD Buy Guide
NVS UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live NVS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
GILD SURGE
7d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live GILD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither NVS nor GILD registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.